January 5, 2018 / 2:08 PM / Updated 8 minutes ago BRIEF-FDA Approves XGEVA (Denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma Reuters Staff 
Jan 5 (Reuters) - Amgen Inc: 
* FDA APPROVES XGEVA® (DENOSUMAB) FOR THE PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH MULTIPLE MYELOMA 
* AMGEN INC - APPROVAL IS BASED ON DATA FROM PIVOTAL PHASE 3 ‘482 STUDY WHICH ENROLLED 1,718 PATIENTS Source text for Eikon: Further company coverage: